PC
AXDX

Palo Capital’s Accelerate Diagnostics AXDX Stock Holding History

Palo Capital’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,340
Closed -$193K – 212
2016
Q1 		$193K Buy
+1,340
New +$189K 0.15% 148

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Palo Capital's AXDX Position: Q2 2016 in Review

Palo Capital sold out of Accelerate Diagnostics (AXDX) in Q2 2016, closing a stake of 1,340 shares — an estimated $193K sold.

Palo Capital first reported a position in AXDX in Q1 2016 and held it in 1 quarter. The position peaked at $193K in Q1 2016. 95 funds tracked by Wall St. Rank hold AXDX as of Q2 2016.

  • Palo Capital reported no remaining Accelerate Diagnostics position as of Q2 2016 after selling out during the quarter.
  • Palo Capital sold 1,340 Accelerate Diagnostics shares in Q2 2016, an estimated $193K.
  • Palo Capital first reported a position in Accelerate Diagnostics in Q1 2016 and held it in 1 quarter.
  • Palo Capital's Accelerate Diagnostics position peaked at $193K in Q1 2016.
  • 95 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2016.

Based on Palo Capital's 13F filing for Q2 2016, filed 20 Jul 2016.